American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 30, Issue 6 , Pages 390-395 , November 2009

Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases

  • Luis Junquera, PhD

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University Central Hospital, Oviedo, Spain
    • Corresponding Author InformationCorresponding author. Department Oral and Maxillofacial Surgery, University Central Hospital, Celestino Villamil s/n, 33009 Oviedo, Spain.
    • ,
  • Lorena Gallego, MD

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University Central Hospital, Oviedo, Spain
    • ,
  • Paz Cuesta, MD

      Affiliations

    • Department of Otorhinolaryngology, University Central Hospital, Oviedo, Spain
    • ,
  • Alejandro Pelaz, MD

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University Central Hospital, Oviedo, Spain
    • ,
  • Juan Carlos de Vicente, PhD

      Affiliations

    • Department of Oral and Maxillofacial Surgery, University Central Hospital, Oviedo, Spain

Received 10 March 2008

References 

  1. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 2006;77:109–117
  2. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186–193
  3. Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:14–21
  4. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433–441
  5. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120–123
  6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117
  7. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws , American Association of Oral and Maxillofacial Surgeons . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–376
  8. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac. 2007;65:415–423
  9. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102
  10. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  11. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–1575
  12. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809
  13. Dello Russo NM, Jeffcoat MK, Marx RE, et al. Osteonecrosis in the jaws of patients who are using oral bisphosphonates to treat osteoporosis. Int J Oral Maxillofac Implants. 2007;22:146–153
  14. Brunski JB. In vivo bone response to biochemical loading at the bone/dental-implant interface. Adv Dent Res. 1999;13:99–119
  15. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy. Ann Oncol. 2006;17:1197–1204
  16. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  17. Magopoulos C, Karakinaris G, Telioudis Z, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007;28:158–163
  18. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–2410
  19. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945–952
  20. Rosen HM, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100–103
  21. Okuno S, Inaba M, Kitatani K, et al. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int. 2005;16:501–509

PII: S0196-0709(08)00146-4

doi: 10.1016/j.amjoto.2008.07.014

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 30, Issue 6 , Pages 390-395 , November 2009

Article Tools

* Image Usage & Resolution